Levacetylleucine - IntraBio
Alternative Names: AQNEURSA; IB-1001 - IntraBio; N-Acetyl-L-Leucine - IntraBioLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator University of Munich; University of Oxford
- Developer IntraBio
- Class Acetamides; Amino acids; Esters; Neuroprotectants; Pentanoic acids; Small molecules; Vestibular disorder therapies
- Mechanism of Action Calcium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Niemann-Pick disease type C
- Phase II Ataxia telangiectasia; Sandhoff disease; Tay-Sachs disease
Most Recent Events
- 04 Nov 2024 IntraBio plans a phase III trial for Ataxia telangiectasia (In children, In adolescents, In adults, In elderly) in the US, Germany, Slovakia, Spain and Switzerland (PO, Suspension) in March 2025 (NCT06673056)
- 24 Sep 2024 Registered for Niemann-Pick disease type C (In adolescents, In children, In adults) in USA (PO)
- 24 Sep 2024 FDA assigns PDUFA action date of (24/09/2024) for levacetylleucine for Niemann-Pick disease type C (IntraBio pipeline, September 2024)